Friday, 19 Jul 2019

You are here

Pregnancy Outcomes Improve in Lupus

Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve. The large decline in in-hospital maternal mortality was greater for lupus pregnancies than for non-lupus pregnancies. Findings from a retrospective cohort study are published in Annals of Internal Medicine.

Researchers examined the the National Inpatient Sample database of hospitalizations of adult pregnant women with and without lupus to assess nationwide trends and disparities in maternal and fetal complications among pregnant women with lupus. They compared An estimated 93 820 pregnant women with SLE and 78 045 054 without SLE were hospitalized in the United States from 1998 through 2015.

Outcomes improved during those 18 years. Regarding in-hospital maternal mortality, lupus patients had greater improvement than those without lupus, with a rate dropping from 34 times higher (442 vs 13 per 100,000) in 1998 to 2000 to less than 5 times higher (<50 vs. 10) in 2013 to 2015.

Fetal mortality rates for SLE patients also declined, but the decrease did not reach statistical significance.

Outcomes in women with lupus in all measures are improving faster with those without lupus.According to the study authors, these findings suggest that lupus pregnancy improvements are significant over the past 18 years.

In this large study examining SLE and non-SLE pregnancies over 18 years, in-hospital maternal mortality and overall outcomes improved markedly, particularly among women with SLE. However, improvement is still needed, because SLE pregnancy risks remain high.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cardiovascular Disease Increased in Hospitalized Lupus Patients

Systemic lupus erythematosus (SLE) patients who are hospitalized have an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) and its individual phenotypes of coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease. 

Blinded by the Use of Antimalarials in Lupus?

Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?

Disparities in Lupus Survival

MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively). Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women with lupus were 2.43 times more likely to die than white women in the general population. None of the white women with lupus died within 5 years of diagnosis, while mortality was elevated for black women from the date of diagnosis on.

DMARD Success in Myositis-Related Interstitial Lung Disease

It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease, and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD cohort has shown that azathioprine and mycophenolate mofetil use is associated improved lung function and less prednisone use.

Sjögren's Syndrome Differs in Minorities

Minority groups in the U.S. have differing rates of Sjögren's syndrome and exhibit distinct clinical patterns of the disease, a large cross-sectional study revealed. The percentage of American Indians in a SS cohort of 610 patients was much higher than expected, at 25.3%, whereas the percentage of African Americans was lower, at 3.1%. In addition, American Indians had higher levels of disease activity and more extraglandular manifestations, whereas African Americans had a symptom pattern associated with subsequent lymphoma development, researchers reported in Arthritis Care & Research.